Third Rock Ventures launches Global Blood Therapeutics
E-mail
|
Print
|
Comments ()
06/14/2012 7:43 AM
Third Rock Ventures LLC, a venture capital firm with offices in Boston and San Francisco, announced Thursday the formation of Global Blood Therapeutics Inc. and its $40.7 million Series A financing.
Global Blood Therapeutics is building a pipeline of medicines for severe genetic blood diseases. The company’s lead program focuses on sickle cell disease.
Global Blood Therapeutics marks the first company formation and launch out of Third Rock Ventures’ West Coast office, the firm said.
Mark A. Goldsmith, a medical doctor with a Ph.D., is the firm’s chief executive. He is also a venture partner at Third Rock.
Chris Reidy can be reached at reidy@globe.com.
MOST E-MAILED »
- Tornado warning issued for southwestern Mass.
- Soldiers flood western Mexico to protect towns
- Coursera to offer new MOOC options for teachers
- Menotomy Grill & Tavern looking to open in Arlington after Memorial Day
- What does the receivers depth chart look like?
- Harvard students demand inquiry into immigration thesis
- Fresh brewed iced coffee from 1369, delivered by bike to your door
